NOT-CA-20-043 - Notice of Special Interest (NOSI): National Cancer Institute Announcement regarding Availability of Competitive Revision SBIR/STTR Supplements on Coronavirus Disease 2019 (COVID-19)
NOT-OD-20-082 - NIH LATE APPLICATION POLICY Due to Public Health Emergency for United States for 2019 Novel Coronavirus (COVID-19)
NOT-OD-20-083 - General Frequently Asked Questions (FAQs) - Proposal Submission and Award Management Related to COVID-19
NOT-OD-20-086 - Flexibilities Available to Applicants and Recipients of Federal Financial Assistance Affected by COVID-19
NOT-OD-20-087 - Guidance for NIH-funded Clinical Trials and Human Subjects Studies Affected by COVID-19
NOT-OD-20-088 - Flexibilities for Assured Institutions for Activities of Institutional Animal Care and Use Committees (IACUCs) Due to COVID-19
NOT-OD-20-091 - UPDATE: NIH Late Application Policy Due to Public Health Emergency for United States for 2019 Novel Coronavirus
Notice of Special Interest (NOSI): NCI SBIR Administrative Supplements for Activities to Accelerate the Development and Commercialization of Cancer-Related Innovations (NOT-CA-20-012)
To accelerate the development of promising technologies, the NCI announces the opportunity for current NCI-funded SBIR Phase I grantees (R43 grant mechanism only) to seek supplemental project funding via the Administrative Supplement mechanism. The funds from these Administrative Supplements are intended to support research activities that are aimed at:
- Achieving next critical milestones in the technology development pathway to make the applicants more competitive for Phase II applications and/or for raising private-sector capital; and
- Accelerating the development of the SBIR product to advance it towards commercialization
Administrative Supplements to Promote Diversity in Research and Development Small Businesses-SBIR/STTR (Admin Supp Clinical Trial Not Allowed) (PA-18-837)
This administrative supplement opportunity is designed to provide support for research and entrepreneurial experiences for individuals from the identified groups throughout the continuum from undergraduate to the faculty level. Application budgets are limited to no more than the amount of the current parent award, and must reflect the actual needs of the proposed project.
Research Supplements to Promote Diversity in Health-Related Research (PA-16-288)
NCI Diversity Supplements support the research training of students, post-baccalaureated and post-Masters individuals, postdoctoral fellows and faculty investigators who are members of an underrepresented group. To be considered for this supplement grant, you need to have a Phase II or Fast-Track SBIR/STTR grant or contract.
Commercialization Readiness Pilot (CRP) Program Technical Assistance (PAR-20-128)
The Funding Opportunity Announcement aims to facilitate the transition of previously funded SBIR and STTR Phase II and Phase IIB projects to the commercialization stage by providing additional support for technical assistance not typically supported through Phase II or Phase IIB grants or contracts. This may include preparation of documents for a FDA submission, development of an intellectual property strategy, and/or planning for a clinical trial. Although a significant amount of the work in a CRP award may be subcontracted to other organizations, the small business concern is expected to maintain oversight and management of the R&D throughout the award. Clinical trials not accepted under this FOA.
In addition to grant and contract funding opportunities, NCI SBIR & STTR offers administrative supplements to assist awardees on their commercialization journey. This page is updated as new funding opportunities are announced. Please visit this page often to view new opportunities.
You may also sign up to receive email updates from NCI SBIR & STTR Programs announcing new funding opportunities. If you would like to receive updates from the NCI SBIR & STTR Programs, please subscribe to our mailing list.